MarginsXMarginsX
Home › Markets › Health Care › ZURA

Zura Bio Limited (ZURA)

ZURA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.08
-12.90% on the day
Market cap
$104.0M
Micro cap
Revenue
Foreign filer: no machine-readable annual figure in SEC data
Net income
Foreign filer: no machine-readable annual figure in SEC data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerZURA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryCayman Islands
IPO yearNot reported by the screener
SEC CIK0001855644
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inCayman Islands

Financials

Foreign filer: no machine-readable annual figure in SEC data.

Warning signs

Cash runway
34.7 months
$187.7M cash at September 30, 2026
Share count, 1 year
+48.1%
2025-11-10 to 2026-10-27 · +121.0% over 3 years
Going-concern doubt
No
10-Q filed October 27, 2026
Insider net buying, 12 months
$12.5M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-10-27
Cash and burn$187.7M cash; operating cash flow -$16.2M a quarter.Report 2026-09-30
Shares outstanding96,325,411 (2026-10-27); 65,023,308 a year earlier; 43,593,678 three years earlier.Cover page 2026-10-27
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-02-25
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorWithumSmith+Brown, PC, East Brunswick, New Jersey, United StatesPCAOB Form AP 2026-03-20
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $12.5M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$25.8M-$19K$187.7MNo debt tagsNeeds four quarters10-Q 2026-10-27
Q2 2026
2026-06-30
Not filed-$26.3M$18.9M$205.1MNo debt tagsNeeds four quarters10-Q 2026-08-11
Q1 2026
2026-03-31
Not filed-$24.2M-$18.9M$225.6MNo debt tagsNeeds four quarters10-Q 2026-05-07
Q4 2025
2025-12-31
Not filed-$17.2M-$64.8M$109.4MNo debt tagsNeeds four quarters10-K 2026-03-19
Q3 2025
2025-09-30
Not filed-$18.0M-$15K$139.0MNo debt tagsNeeds four quarters10-Q 2026-10-27
Q2 2025
2025-06-30
Not filed-$16.0M$11.0M$154.5MNo debt tagsNeeds four quarters10-Q 2026-08-11
Q1 2025
2025-03-31
Not filed-$17.4M-$11.1M$170.6MNo debt tagsNeeds four quarters10-Q 2026-05-07
Q4 2024
2024-12-31
Not filed-$13.6M-$10.8M$176.5MNo debt tagsNeeds four quarters10-K 2026-03-19

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
FORM S-3
S-32026-10-27
Latest annual report10-K2026-03-19
Latest quarterly / interim10-Q2026-10-27
Latest current report
FORM 8-K
8-K2026-11-09
Latest proxyDEFA14A2026-05-22

Source: SEC EDGAR submissions feed, 447 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-69.7%
1 month-70.7%
3 months-78.0%
Year to date-76.3%
1 year-70.3%
From 52-week high-82.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
VYGRVoyager Therapeutics Inc.$1.63-5.78%$101.4M
MOLNMolecular Partners AG$2.70-8.21%$101.2M
ARMPArmata Pharmaceuticals Inc.$2.99-22.74%$111.2M
OTLKOutlook Therapeutics Inc.$0.3960-4.12%$96.4M
CMPXCompass Therapeutics Inc.$0.6615-14.51%$119.1M
LENZLENZ Therapeutics Inc.$3.82-7.51%$120.0M
BDTXBlack Diamond Therapeutics Inc.$1.53+4.08%$87.9M
CRDLCardiol Therapeutics Inc. Class A Common Shares$0.9798-2.02%$125.1M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier